Literature DB >> 7283046

Esthesioneuroblastoma.

J P Shah, J Feghali.   

Abstract

A retrospective review of the clinical records of 31 patients with esthesioneuroblastoma is presented. A bimodal age distribution was noted. The tumor is extremely rare among blacks. Most patients presented with locally advanced disease. However, regional and distant metastases at the time of initial diagnosis are uncommon. Local recurrence at the primary site was very common, and this reflects either the conservative initial surgical treatment employed or the multicentric nature of the tumor. Cervical lymph node metastasis is present in less than 10 percent of patients at the time of diagnosis. Survival rates were better in patients with early stages of disease. From this study we conclude that the current management of these tumors should consist of a combination of radiation and surgery. Radical resection followed by postoperative radiotherapy appears to be the treatment combination of choice. The 5 year survival rate in our series was 52 percent.

Entities:  

Mesh:

Year:  1981        PMID: 7283046     DOI: 10.1016/0002-9610(81)90374-3

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  4 in total

1.  Olfactory neuroblastomas: survival rate and prognostic factor.

Authors:  Sung-Kyun Hwang; Sun-Ha Paek; Dong Gyu Kim; Yoon-Kyung Jeon; Je G Chi; Hee-Won Jung
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

2.  Treatment of esthesioneuroblastoma with chemotherapy: a report of two cases.

Authors:  D O Heros; F H Hochberg
Journal:  J Neurooncol       Date:  1988-09       Impact factor: 4.130

3.  Esthesioneuroblastoma: endonasal endoscopic treatment.

Authors:  Paolo G Castelnuovo; Giovanni Delù; Federica Sberze; Andrea Pistochini; Cristhian Cambria; Paolo Battaglia; Maurizio Bignami
Journal:  Skull Base       Date:  2006-02

Review 4.  Review of skull base surgery approaches: with special reference to pediatric patients.

Authors:  J D Kennedy; S J Haines
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.